A case of exacerbation of ulcerative colitis induced by combination therapy with PEG-interferon  -2b and ribavirin

Watanabe, Toshio; Inoue, Machiko; Harada, Kenichi; Homma, Nobuyuki; Uchida, Misako; Ogata, Noriyuki; Funada, Riko; Hasegawa, Katsuhiko; Soga, Kenji; Shibasaki, Koichi

doi:10.1136/gut.2006.105197

Cited by 38 publications

(37 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Etanercept has been used successfully as prophylaxis against psoriasis in chronic hepatitis C patients undergoing IFN therapy [135] . It should be noted, however, that exacerbation of IBD has been reported with IFN therapy, requiring its discontinuation [136] .…”

Section: Hepatic Injury From Reactivation Of Viral Hepatitis On Ibd Tmentioning

confidence: 99%

Hepatotoxicity of Agents Used in the Management of Inflammatory Bowel Disease

Khokhar

Lewis²

2010

Dig Dis

View full text Add to dashboard Cite

Patients with inflammatory bowel disease (IBD) are at risk for hepatobiliary disease and toxicity, and the diagnosis of drug-induced liver disease in patients being treated for IBD can represent a clinical challenge. There are a number of disease states associated with IBD, which are primary sclerosing cholangitis, cholangiocarcinoma and autoimmune hepatitis. There is a wide spectrum of hepatic injury that can occur from the agents used to treat IBD, such as acute or chronic hepatic injury directly attributable to the drugs used to treat IBD (e.g. sulfasalazine, mesalamine, thiopurines, methotrexate, TNF antagonists, quinolone antibiotics); liver toxicity from drugs used to treat complications of immunomodulators and TNF antagonists (e.g. isoniazid for treatment of reactivation tuberculosis), and exacerbation of underlying chronic viral hepatitis with infliximab and other TNF antagonists. Thiopurines are also associated with the development of hepatic vascular lesions, such as nodular regenerative hyperplasia and peliosis hepatic. In addition, biologics can be associated with the reactivation of underlying chronic viral hepatitis, mandating universal screening prior to initiation of TNF-alpha antagonist therapy.

show abstract

Section: Hepatic Injury From Reactivation Of Viral Hepatitis On Ibd Tmentioning

confidence: 99%

Hepatotoxicity of Agents Used in the Management of Inflammatory Bowel Disease

Khokhar

Lewis²

2010

Dig Dis

View full text Add to dashboard Cite

show abstract

“…11,113,124,125 However, case reports have observed new-onset UC during interferon-a treatment or exacerbation of existing UC (or IBD with a predominance of UC). 116,[124][125][126][127][128][129][130][131][132][133] In one of these case reports, the administration of sulfasalazine allowed the patient to receive interferon-a again without a flare-up of UC. 126 This case suggests the possible efficacy of sulfasalazine therapy in patients with UC complicated by administration of interferon-a.…”

Section: What Is the Risk Of Exacerbation Of Ibd With Interferon?mentioning

confidence: 99%

Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease

Gisbert

Chaparro

Esteve

2011

Alimentary Pharmacology &Amp; Therapeutics

104

View full text Add to dashboard Cite

“…On the other hand, the chronic use of immunomodulators to treat IBD could potentially make the hepatitis C worse. Of these 12 case reports, there are two cases of new onset Crohn's disease [4], eight cases of ulcerative colitis including six new onset UC [5][6][7][8] and two UC exacerbations [9,10], and two cases of ''IBD-like colitis'' [11]. Six cases involved combination therapy with pegylated interferon (PEGIFN) and ribavirin, the other six involved interferon (IFN) monotherapy.…”

Section: Review Of Case Reportsmentioning

confidence: 99%

“…Moreover, several case studies have reported worsening or onset of IBD while patients are being treated for HCV [4][5][6][7][8][9][10][11]. On the other hand, the chronic use of immunomodulators to treat IBD could potentially make the hepatitis C worse.…”

Section: Review Of Case Reportsmentioning

confidence: 99%

See 1 more Smart Citation

Hepatitis C Virus and Inflammatory Bowel Disease

et al. 2008

View full text Add to dashboard Cite

Gastroenterologists frequently treat patients with complex illnesses such as chronic hepatitis C infections and inflammatory bowel disease (IBD). Occasionally, a patient will present with these two diseases which behave very differently and the treatment for one may potentially exacerbate the other. The purpose of this article is to review the current literature regarding hepatitis C virus therapy in the setting of IBD as well as the effects of common IBD therapies on the hepatitis C virus. Based on limited data, anti-viral therapy is probably safe in patients with well-controlled IBD, but there might be a risk of causing new onset of IBD. Also, it does not appear that the commonly used medications for IBD have much of an effect on the hepatitis C virus (HCV) or its course.

show abstract

A case of exacerbation of ulcerative colitis induced by combination therapy with PEG-interferon -2b and ribavirin

Cited by 38 publications

References 4 publications

Hepatotoxicity of Agents Used in the Management of Inflammatory Bowel Disease

Hepatotoxicity of Agents Used in the Management of Inflammatory Bowel Disease

Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease

Hepatitis C Virus and Inflammatory Bowel Disease

Contact Info

Product

Resources

About